While age-based targeting greatly reduces the number of deaths over the long-term, it comes at the cost of slightly more AIDS deaths relative to CD4-based targeting in the years immediately following the TasP campaign (as illustrated in Fig 2I). Here, CD4 is linked to AIDS.